副腎皮質がんの世界市場レポート 2025年

副腎皮質がんの市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR4.4％で44億7,000万米ドルに成長します。予測期間中の成長は、併用療法の拡大、個別化医療の採用の増加、臨床試験の拡大、国際研究ネットワークへの関与の増加、政府および研究資金の増加など、いくつかの要因によるものと考えられます。この期間に予想される主な動向には、ゲノム配列決定と個別化医療の進展、標的療法の革新、免疫療法の発展、リキッドバイオプシー技術の進歩、バイオマーカー同定の改善などがあります。

希少がんの有病率の上昇が、今後の副腎皮質がん（ACC）市場の成長を牽引すると予想されます。希少がんは罹患率が低く、患者の転帰に大きな影響を与えるという特徴があり、診断や治療に専門的な技術が必要とされます。希少がん症例の増加は、副腎皮質がんの発見を向上させ、以前は診断されなかったかもしれない症例の早期発見を可能にした診断方法の進歩など、さまざまな要因によるものです。副腎皮質がんは、比較的まれながんでありながら侵攻性の強いがんであるため、希少がんの有病率の増加に寄与しており、より良い診断と治療アプローチの必要性が強調されています。例えば、世界保健機関（WHO）の一部である国際がん研究機関の報告書（2022年2月）によると、米国では10万人当たり年間6人近くが新たに希少がんと診断されています。その結果、希少がんの有病率の増加が副腎皮質がん市場の拡大に拍車をかけると予想されます。

副腎皮質がん（ACC）市場の主なプレーヤーは、特定の腫瘍経路を標的とし、患者の予後を改善する低分子薬などの革新的な治療法の開発に注力しています。低分子医薬品は、細胞内に入り込んでタンパク質や酵素を標的とする低分子化合物であり、それによって生物学的プロセスを制御し、腫瘍増殖経路を阻害することによって副腎皮質がんのような疾患を治療します。例えば、2023年1月、米国の製薬会社Orphagen Pharmaceuticals, Inc.は、小児副腎皮質がん（ACC）の治療薬として開発中の治験薬OR-449について、米国食品医薬品局（FDA）から希少小児疾患指定（RPDD）を受けたと発表しました。この薬剤は、主に小児が罹患する希少で侵攻性のがんである小児ACCを特にターゲットとしています。小児ACCは、主に小児が罹患するまれながんであり、多くの場合、男性化、クッシング症候群など、ホルモンの過剰分泌に関連した症状を示します。診断は通常、画像診断とホルモン評価によって行われ、予後は診断時の年齢や腫瘍の切除可能性などの要因に影響されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界副腎皮質がんPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の副腎皮質がん市場：成長率分析
• 世界の副腎皮質がん市場の実績：規模と成長, 2019-2024
• 世界の副腎皮質がん市場の予測：規模と成長, 2024-2029, 2034F
• 世界副腎皮質がん総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の副腎皮質がん市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ローカライズされた副腎皮質がん
• 転移性副腎皮質がん
• 世界の副腎皮質がん市場：セラピー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 手術
• 腹腔鏡手術
• 開腹手術
• 化学療法
• 標的療法
• 放射線治療
• 外部放射線療法
• 近接放射線療法
• 補助療法
• その他の治療法
• 世界の副腎皮質がん市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 外来手術センター
• がん調査機関
• 世界の副腎皮質がん市場局所性副腎皮質がんの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 初期段階のローカライズ副腎皮質がん
• 高度なローカライズされた副腎皮質がん
• 世界の副腎皮質がん市場転移性副腎皮質がんの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遠隔臓器への転移
• 局所転移

第7章 地域別・国別分析

• 世界の副腎皮質がん市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の副腎皮質がん市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 副腎皮質がん市場：競合情勢
• 副腎皮質がん市場：企業プロファイル
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Medtronic plc
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Sun Pharmaceutical Industries Ltd.
• Ipsen S.A.
• Ferring Pharmaceuticals Inc.
• Exelixis Inc.
• Alnylam Pharmaceuticals Inc.
• Mylan N.V.
• HRA Pharma S.A.
• Servier Laboratories
• Tempest Therapeutics Inc.
• Orphagen Pharmaceuticals Inc.
• Millendo Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 副腎皮質がん市場2029：新たな機会を提供する国
• 副腎皮質がん市場2029：新たな機会を提供するセグメント
• 副腎皮質がん市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Adrenocortical carcinoma (ACC) is a rare and aggressive form of cancer that begins in the outer layer (cortex) of the adrenal glands. The adrenal glands are small, triangular organs located on top of each kidney and are responsible for producing hormones that regulate metabolism, immune function, blood pressure, and stress response. ACC can disrupt hormone production, leading to symptoms such as weight gain, high blood pressure, and virilization (the development of male physical traits).

There are two main types of adrenocortical carcinoma, localized and metastatic. Localized adrenocortical carcinoma is a rare and aggressive cancer that remains confined to the adrenal gland, without spreading to other areas of the body. Treatment for these conditions involves various methods, including surgery, chemotherapy, targeted therapy, radiation therapy, and adjuvant therapy. The primary end users of these treatments are hospitals, clinics, ambulatory surgical centers, and cancer research institutions.

The adrenocortical carcinoma market research report is one of a series of new reports from The Business Research Company that provides adrenocortical carcinoma market statistics, including the adrenocortical carcinoma industry global market size, regional shares, competitors with the adrenocortical carcinoma market share, detailed adrenocortical carcinoma market segments, market trends, and opportunities, and any further data you may need to thrive in the adrenocortical carcinoma industry. This adrenocortical carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The adrenocortical carcinoma market size has grown steadily in recent years. It will grow from $3.60 billion in 2024 to $3.77 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth during the historic period can be attributed to several factors, including the rising incidence of adrenocortical carcinoma, greater awareness of rare endocrine tumors, and increased government and research funding. Additionally, the growing presence of patient support and advocacy groups, along with the rising prevalence of rare cancers, contributed to this growth.

The adrenocortical carcinoma market size is expected to see steady growth in the next few years. It will grow to $4.47 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth during the forecast period can be attributed to several factors, including the greater use of combination therapies, the rising adoption of personalized medicine, the expansion of clinical trials, increased involvement in international research networks, and a boost in government and research funding. Key trends expected during this period include advancements in genomic sequencing and personalized medicine, innovations in targeted therapies, developments in immunotherapy, progress in liquid biopsy technology, and improvements in biomarker identification.

The rising prevalence of rare cancers is expected to drive the growth of the adrenocortical carcinoma (ACC) market in the future. Rare cancers are characterized by their low incidence rates and their significant impact on patient outcomes, requiring specialized techniques for diagnosis and treatment. The increase in rare cancer cases can be attributed to various factors, including advancements in diagnostic methods that have improved the detection of adrenocortical carcinoma, enabling earlier identification of cases that might have previously gone undiagnosed. Adrenocortical carcinoma, a relatively uncommon yet aggressive form of cancer, contributes to the growing prevalence of rare cancers, emphasizing the need for better diagnosis and treatment approaches. For example, a report from the International Agency for Research on Cancer, part of the World Health Organization, noted in February 2022 that nearly six new cases of rare cancers are diagnosed annually per 100,000 individuals in the US. As a result, the increase in the prevalence of rare cancers is expected to fuel the expansion of the adrenocortical carcinoma market.

Key players in the adrenocortical carcinoma (ACC) market are focusing on the development of innovative therapies, such as small-molecule drugs, to target specific tumor pathways and enhance patient outcomes. Small-molecule drugs are low molecular weight compounds that enter cells to target proteins or enzymes, thereby regulating biological processes and treating diseases such as adrenocortical carcinoma by inhibiting tumor growth pathways. For example, in January 2023, Orphagen Pharmaceuticals, Inc., a pharmaceutical company based in the United States, announced that the U.S. Food and Drug Administration (FDA) had granted Rare Pediatric Disease Designation (RPDD) for its investigational drug OR-449, which is being developed to treat pediatric adrenocortical carcinoma (ACC). This drug specifically targets pediatric ACC, a rare and aggressive cancer that primarily affects children. The disease often manifests with symptoms related to hormonal overproduction, such as virilization and Cushing syndrome. Diagnosis is typically carried out through imaging and hormonal assessments, with prognosis influenced by factors such as the age of diagnosis and the resectability of the tumor.

In October 2024, Esteve Pharmaceuticals, S.A., a pharmaceutical company based in Spain, acquired HRA Pharma Rare Diseases from Perrigo Company plc for an undisclosed amount. Through this acquisition, Esteve Pharmaceuticals seeks to broaden its portfolio of treatments for rare diseases, accelerate its international expansion, improve patient care, and expand its market presence. HRA Pharma Rare Diseases, based in France, is a pharmaceutical company focused on treating rare diseases, including adrenocortical carcinoma.

Major players in the adrenocortical carcinoma market are Roche Holding AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Medtronic plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Ferring Pharmaceuticals Inc., Exelixis Inc., Alnylam Pharmaceuticals Inc., Mylan N.V., HRA Pharma S.A., Servier Laboratories, Tempest Therapeutics Inc., Orphagen Pharmaceuticals Inc., and Millendo Therapeutics Inc.

North America was the largest region in the adrenocortical carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in adrenocortical carcinoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the adrenocortical carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The adrenocortical carcinoma market consists of revenues earned by entities by providing services such as diagnostic services, medical treatments, patient management services, clinical trials, and research. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adrenocortical Carcinoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on adrenocortical carcinoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for adrenocortical carcinoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adrenocortical carcinoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Localized Adrenocortical Carcinoma; Metastatic Adrenocortical Carcinoma
• 2) By Therapy: Surgery; Laparoscopic Surgery; Open Surgery; Chemotherapy; Targeted Therapy; Radiation Therapy; External Beam Radiation Therapy; Bratchytherapy; Adjuvant Therapy; Other Therapy
• 3) By End User: Hospitals And Clinics; Ambulatory Surgical Centers; Cancer Research Institutes
• Subsegments:
• 1) By Localized Adrenocortical Carcinoma: Early-Stage Localized Adrenocortical Carcinoma; Advanced Localized Adrenocortical Carcinoma
• 2) By Metastatic Adrenocortical Carcinoma: Metastasis To Distant Organs; Local Regional Metastasis
• Companies Mentioned: Roche Holding AG; Merck & Co. Inc.; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Adrenocortical Carcinoma Market Characteristics

3. Adrenocortical Carcinoma Market Trends And Strategies

4. Adrenocortical Carcinoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Adrenocortical Carcinoma Growth Analysis And Strategic Analysis Framework

• 5.1. Global Adrenocortical Carcinoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Adrenocortical Carcinoma Market Growth Rate Analysis
• 5.4. Global Adrenocortical Carcinoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Adrenocortical Carcinoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Adrenocortical Carcinoma Total Addressable Market (TAM)

6. Adrenocortical Carcinoma Market Segmentation

• 6.1. Global Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Localized Adrenocortical Carcinoma
• Metastatic Adrenocortical Carcinoma
• 6.2. Global Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Laparoscopic Surgery
• Open Surgery
• Chemotherapy
• Targeted Therapy
• Radiation Therapy
• External Beam Radiation Therapy
• Brachytherapy
• Adjuvant Therapy
• Other Therapy
• 6.3. Global Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Ambulatory Surgical Centers
• Cancer Research Institutes
• 6.4. Global Adrenocortical Carcinoma Market, Sub-Segmentation Of Localized Adrenocortical Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early-Stage Localized Adrenocortical Carcinoma
• Advanced Localized Adrenocortical Carcinoma
• 6.5. Global Adrenocortical Carcinoma Market, Sub-Segmentation Of Metastatic Adrenocortical Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Metastasis To Distant Organs
• Local Regional Metastasis

7. Adrenocortical Carcinoma Market Regional And Country Analysis

• 7.1. Global Adrenocortical Carcinoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Adrenocortical Carcinoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Adrenocortical Carcinoma Market

• 8.1. Asia-Pacific Adrenocortical Carcinoma Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Adrenocortical Carcinoma Market

• 9.1. China Adrenocortical Carcinoma Market Overview
• 9.2. China Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Adrenocortical Carcinoma Market

• 10.1. India Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Adrenocortical Carcinoma Market

• 11.1. Japan Adrenocortical Carcinoma Market Overview
• 11.2. Japan Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Adrenocortical Carcinoma Market

• 12.1. Australia Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Adrenocortical Carcinoma Market

• 13.1. Indonesia Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Adrenocortical Carcinoma Market

• 14.1. South Korea Adrenocortical Carcinoma Market Overview
• 14.2. South Korea Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Adrenocortical Carcinoma Market

• 15.1. Western Europe Adrenocortical Carcinoma Market Overview
• 15.2. Western Europe Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Adrenocortical Carcinoma Market

• 16.1. UK Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Adrenocortical Carcinoma Market

• 17.1. Germany Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Adrenocortical Carcinoma Market

• 18.1. France Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Adrenocortical Carcinoma Market

• 19.1. Italy Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Adrenocortical Carcinoma Market

• 20.1. Spain Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Adrenocortical Carcinoma Market

• 21.1. Eastern Europe Adrenocortical Carcinoma Market Overview
• 21.2. Eastern Europe Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Adrenocortical Carcinoma Market

• 22.1. Russia Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Adrenocortical Carcinoma Market

• 23.1. North America Adrenocortical Carcinoma Market Overview
• 23.2. North America Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Adrenocortical Carcinoma Market

• 24.1. USA Adrenocortical Carcinoma Market Overview
• 24.2. USA Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Adrenocortical Carcinoma Market

• 25.1. Canada Adrenocortical Carcinoma Market Overview
• 25.2. Canada Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Adrenocortical Carcinoma Market

• 26.1. South America Adrenocortical Carcinoma Market Overview
• 26.2. South America Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Adrenocortical Carcinoma Market

• 27.1. Brazil Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Adrenocortical Carcinoma Market

• 28.1. Middle East Adrenocortical Carcinoma Market Overview
• 28.2. Middle East Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Adrenocortical Carcinoma Market

• 29.1. Africa Adrenocortical Carcinoma Market Overview
• 29.2. Africa Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Adrenocortical Carcinoma Market Competitive Landscape And Company Profiles

• 30.1. Adrenocortical Carcinoma Market Competitive Landscape
• 30.2. Adrenocortical Carcinoma Market Company Profiles
  • 30.2.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Adrenocortical Carcinoma Market Other Major And Innovative Companies

• 31.1. Medtronic plc
• 31.2. Eli Lilly and Company
• 31.3. Teva Pharmaceutical Industries Ltd.
• 31.4. Astellas Pharma Inc.
• 31.5. Sun Pharmaceutical Industries Ltd.
• 31.6. Ipsen S.A.
• 31.7. Ferring Pharmaceuticals Inc.
• 31.8. Exelixis Inc.
• 31.9. Alnylam Pharmaceuticals Inc.
• 31.10. Mylan N.V.
• 31.11. HRA Pharma S.A.
• 31.12. Servier Laboratories
• 31.13. Tempest Therapeutics Inc.
• 31.14. Orphagen Pharmaceuticals Inc.
• 31.15. Millendo Therapeutics Inc.

32. Global Adrenocortical Carcinoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Adrenocortical Carcinoma Market

34. Recent Developments In The Adrenocortical Carcinoma Market

35. Adrenocortical Carcinoma Market High Potential Countries, Segments and Strategies

• 35.1 Adrenocortical Carcinoma Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Adrenocortical Carcinoma Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Adrenocortical Carcinoma Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer